Arne Helland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Arne Helland has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Olav Spigset
Department of Clinical Pharmacology, St. Olav University Hospital, Trondheim, Norway
7 shared publications - Hege-Merete Krabseth
Department of Clinical Pharmacology, Clinic of Laboratory Medicine St. Olav University Hospital Trondheim Norway
5 shared publications - Magnus Strømmen
Centre for Obesity Research, Clinic of Surgery, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
5 shared publications - Georgios Schoretsanitis
Department of Psychiatry, Lausanne University Hospital and University of Lausanne, CH-1008 Prilly Lausanne, Switzerland; Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neurosciences, Lausanne University Hospital and University of Lausanne, CH-1005 Lausanne, Switzerland; The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, NY 11004, USA; Department of Psychiatry, Zucker School of Medicine at Northwell/Hofstra, Hempstead, NY 11549, USA
3 shared publications Olav Spigset
Department of Clinical Pharmacology, St. Olav University Hospital , NO-7006 Trondheim
3 shared publicationsHege-Merete Krabseth
Affiliation Department of Clinical Pharmacology, Clinic of Laboratory Medicine, St. Olav University Hospital, Trondheim, Norway
2 shared publications
Latest Publications
- Open Access
- 27 November 2025
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 137 (6) , e70149
Effect of Bariatric Surgery on the Pharmacokinetics of Codeine, Oxycodone and Tramadol—A Case Series
Background: The impact of bariatric surgery on the pharmacokinetics of codeine, oxycodone or tramadol is largely unknown. Methods: In patients treated with these opioids before and after bariatric surgery, serial drug concentrations were measured throughout a dose interval preoperatively and 1, 6 and 12 months postoperatively. Results: Eight patients treated with codeine ( n = 2), oxycodone ( n = 2) or tramadol ( n = 4) were included. In the patients using codeine, the area under the concentration–time curve during a dose interval (AUC) was moderately increased for the active metabolites morphine and morphine 6‐glucuronide 6–12 months after bariatric surgery. For oxycodone, there were only negligible AUC changes. In the tramadol group, there were no discernible AUC changes considered to be caused by the surgical procedure. There were no apparent changes in maximum concentrations or times to achieve maximum concentrations after surgery for any of the drugs or their metabolites. Conclusion: From a pharmacokinetic point of view, we found no evidence that particular follow‐up procedures should be needed for codeine, oxycodone and tramadol in patients undergoing bariatric surgery and continuing drug treatment. However, as always, doses should be adjusted based on clinical effect and the occurrence of adverse drug reactions.
- 27 November 2025
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 137 (6) , e70149
Open AccessEffect of Bariatric Surgery on the Pharmacokinetics of Codeine, Oxycodone and Tramadol—A Case Series
Background: The impact of bariatric surgery on the pharmacokinetics of codeine, oxycodone or tramadol is largely unknown. Methods: In patients treated with these opioids before and after bariatric surgery, serial drug concentrations were measured throughout a dose interval preoperatively and 1, 6 and 12 months postoperatively. Results: Eight patients treated with codeine ( n = 2), oxycodone ( n = 2) or tramadol ( n = 4) were included. In the patients using codeine, the area under the concentration–time curve during a dose interval (AUC) was moderately increased for the active metabolites morphine and morphine 6‐glucuronide 6–12 months after bariatric surgery. For oxycodone, there were only negligible AUC changes. In the tramadol group, there were no discernible AUC changes considered to be caused by the surgical procedure. There were no apparent changes in maximum concentrations or times to achieve maximum concentrations after surgery for any of the drugs or their metabolites. Conclusion: From a pharmacokinetic point of view, we found no evidence that particular follow‐up procedures should be needed for codeine, oxycodone and tramadol in patients undergoing bariatric surgery and continuing drug treatment. However, as always, doses should be adjusted based on clinical effect and the occurrence of adverse drug reactions.
- Open Access
- 26 March 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (3) , e0319912
Effects of sleeve gastrectomy and Roux-en-Y gastric bypass on the pharmacokinetics of gabapentin and pregabalin: A cohort study
Background: Bariatric surgery may affect the pharmacokinetics of medications by altering the gastrointestinal physiology. Pharmacokinetic changes of first-line neuropathic pain medications such as gabapentin and pregabalin following bariatric treatment have barely been investigated. Methods: In our prospective five-case study we included gabapentin- or pregabalin-treated patients undergoing bariatric surgery at hospitals in Central Norway. Concentrations of gabapentin and pregabalin were assessed using serial blood samples over a dose interval, preoperatively and one, six and twelve months postoperatively. The primary outcomes of the study included changes in area under the time-concentration curve (AUC) with secondary outcomes comprising full pharmacokinetic profiling. Formal statistical testing was not performed due to few cases. Results: Three pregabalin-treated obese patients undergoing Roux-en-Y gastric bypass (RYGB) and two gabapentin-treated patients undergoing RYGB (n = 1) and sleeve gastrectomy (SG) (n = 1) were included. Largest changes for dose-adjusted AUC values after surgery were seen in pregabalin-treated patients at one and six months (average increases of 53% one month and 28% 6 months postoperatively). In the patients on gabapentin, mean AUC changes were less than 10% from baseline throughout the study period. The inter-individual variation was high. Conclusion: Postoperative pharmacokinetic changes for gabapentin were minimal, but for pregabalin we observed more pronounced changes, particularly in one patient. Due to few cases, the results should be interpreted with caution. Given the large inter-individual variation, therapeutic drug monitoring could be considered to capture pharmacokinetic changes and guide dose adjustments postoperatively.
- 26 March 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (3) , e0319912
Open AccessEffects of sleeve gastrectomy and Roux-en-Y gastric bypass on the pharmacokinetics of gabapentin and pregabalin: A cohort study
Background: Bariatric surgery may affect the pharmacokinetics of medications by altering the gastrointestinal physiology. Pharmacokinetic changes of first-line neuropathic pain medications such as gabapentin and pregabalin following bariatric treatment have barely been investigated. Methods: In our prospective five-case study we included gabapentin- or pregabalin-treated patients undergoing bariatric surgery at hospitals in Central Norway. Concentrations of gabapentin and pregabalin were assessed using serial blood samples over a dose interval, preoperatively and one, six and twelve months postoperatively. The primary outcomes of the study included changes in area under the time-concentration curve (AUC) with secondary outcomes comprising full pharmacokinetic profiling. Formal statistical testing was not performed due to few cases. Results: Three pregabalin-treated obese patients undergoing Roux-en-Y gastric bypass (RYGB) and two gabapentin-treated patients undergoing RYGB (n = 1) and sleeve gastrectomy (SG) (n = 1) were included. Largest changes for dose-adjusted AUC values after surgery were seen in pregabalin-treated patients at one and six months (average increases of 53% one month and 28% 6 months postoperatively). In the patients on gabapentin, mean AUC changes were less than 10% from baseline throughout the study period. The inter-individual variation was high. Conclusion: Postoperative pharmacokinetic changes for gabapentin were minimal, but for pregabalin we observed more pronounced changes, particularly in one patient. Due to few cases, the results should be interpreted with caution. Given the large inter-individual variation, therapeutic drug monitoring could be considered to capture pharmacokinetic changes and guide dose adjustments postoperatively.
- Open Access
- 19 December 2024
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 49 (2) , 65-72
Drug detection in oral fluid and urine after single therapeutic doses of dexamphetamine, lisdexamphetamine, and methylphenidate in healthy volunteers
Dexamphetamine, lisdexamphetamine, and methylphenidate are central stimulant drugs widely used to treat attention-deficit/hyperactivity disorder (ADHD), but poor adherence may lead to treatment failure, and the drugs are also subject to misuse and diversion. Drug analysis in oral fluid may thus be useful for monitoring adherence and misuse. We measured drug concentrations in oral fluid and urine after controlled dosing to investigate detection windows and evaluate the chosen cutoffs. Healthy volunteers ingested single oral doses of 10 mg dexamphetamine (n = 11), 30 mg lisdexamphetamine (n = 11), or 20 mg methylphenidate (n = 10), after which they collected parallel oral fluid and urine samples every 8 h for 4–6 days. Amphetamine (analytical cutoff, oral fluid: 1.5 ng/mL; urine: 50 ng/mL), methylphenidate (oral fluid: 0.06 ng/mL), and ritalinic acid (urine: 500 ng/mL) were analyzed using fully validated chromatographic methods. The median time from ingestion to the last detection in oral fluid was 67 ± 4.9 h (lisdexamphetamine) and 69 ± 8.8 h (dexamphetamine) for amphetamine and 36 ± 2.5 h for methylphenidate. This was comparable to urine (77 ± 5.1 h for lisdexamphetamine, 78 ± 4.5 h for dexamphetamine, and 41 ± 2.4 h for ritalinic acid). The interindividual variability in detection times was large, probably in part due to pH-dependent disposition. Using a logistic regression approach, we found similar detection rates as a function of time since intake in urine and oral fluid with the chosen cutoffs, with a high degree of probability for detection at least 24 h after intake of a low therapeutic dose. This demonstrates the usefulness of oral fluid as a test matrix to assess adherence to ADHD medications, provided that the analytical method is sensitive, requiring a cutoff as low as 0.1 ng/mL for methylphenidate. Detection windows similar to those in urine may be achieved for amphetamine and methylphenidate in oral fluid.
- 19 December 2024
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 49 (2) , 65-72
Open AccessDrug detection in oral fluid and urine after single therapeutic doses of dexamphetamine, lisdexamphetamine, and methylphenidate in healthy volunteers
Dexamphetamine, lisdexamphetamine, and methylphenidate are central stimulant drugs widely used to treat attention-deficit/hyperactivity disorder (ADHD), but poor adherence may lead to treatment failure, and the drugs are also subject to misuse and diversion. Drug analysis in oral fluid may thus be useful for monitoring adherence and misuse. We measured drug concentrations in oral fluid and urine after controlled dosing to investigate detection windows and evaluate the chosen cutoffs. Healthy volunteers ingested single oral doses of 10 mg dexamphetamine (n = 11), 30 mg lisdexamphetamine (n = 11), or 20 mg methylphenidate (n = 10), after which they collected parallel oral fluid and urine samples every 8 h for 4–6 days. Amphetamine (analytical cutoff, oral fluid: 1.5 ng/mL; urine: 50 ng/mL), methylphenidate (oral fluid: 0.06 ng/mL), and ritalinic acid (urine: 500 ng/mL) were analyzed using fully validated chromatographic methods. The median time from ingestion to the last detection in oral fluid was 67 ± 4.9 h (lisdexamphetamine) and 69 ± 8.8 h (dexamphetamine) for amphetamine and 36 ± 2.5 h for methylphenidate. This was comparable to urine (77 ± 5.1 h for lisdexamphetamine, 78 ± 4.5 h for dexamphetamine, and 41 ± 2.4 h for ritalinic acid). The interindividual variability in detection times was large, probably in part due to pH-dependent disposition. Using a logistic regression approach, we found similar detection rates as a function of time since intake in urine and oral fluid with the chosen cutoffs, with a high degree of probability for detection at least 24 h after intake of a low therapeutic dose. This demonstrates the usefulness of oral fluid as a test matrix to assess adherence to ADHD medications, provided that the analytical method is sensitive, requiring a cutoff as low as 0.1 ng/mL for methylphenidate. Detection windows similar to those in urine may be achieved for amphetamine and methylphenidate in oral fluid.
- Open Access
- 4 November 2024
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 136 (1)
Effect of bariatric surgery on the pharmacokinetics of drugs used for attention‐deficit hyperactivity disorder—A case series
Background: Changes in gastrointestinal physiology following bariatric surgery may affect the pharmacokinetics of drugs. Data on the impact of bariatric surgery on drugs used for attention‐deficit/hyperactivity disorder (ADHD) are limited.Methods: In patients treated with ADHD medication and undergoing bariatric surgery, serial drug concentrations were measured for 24 h preoperatively and one, six and 12 months postoperatively. Primary outcome was change in area under the concentration‐time curve from 0 to 24 h (AUC0–24), with other pharmacokinetic variables as secondary outcomes.Results: Eight patients treated with lisdexamphetamine (n = 4), dexamphetamine (n = 1), methylphenidate (n = 1) and atomoxetine (n = 2) were included. In total, 409 samples were analysed. Patients underwent sleeve gastrectomy (n = 5) and Roux‐en‐Y gastric bypass (n = 3). AUC0–24 and Cmax of dexamphetamine increased after surgery in those using the prodrug lisdexamphetamine. There was no clear‐cut reduction in tmax postoperatively. For ritalinic acid and atomoxetine, no changes in AUC0–24 were observed, but for atomoxetine, a higher Cmax and a shorter tmax were observed postoperatively.Conclusion: Bariatric surgery may increase the systemic exposure of dexamphetamine after intake of lisdexamphetamine. Patients using lisdexamphetamine should be followed with regard to adverse drug reactions after bariatric surgery, and, if available, therapeutic drug monitoring should be considered.
- 4 November 2024
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 136 (1)
Open AccessEffect of bariatric surgery on the pharmacokinetics of drugs used for attention‐deficit hyperactivity disorder—A case series
Background: Changes in gastrointestinal physiology following bariatric surgery may affect the pharmacokinetics of drugs. Data on the impact of bariatric surgery on drugs used for attention‐deficit/hyperactivity disorder (ADHD) are limited.Methods: In patients treated with ADHD medication and undergoing bariatric surgery, serial drug concentrations were measured for 24 h preoperatively and one, six and 12 months postoperatively. Primary outcome was change in area under the concentration‐time curve from 0 to 24 h (AUC0–24), with other pharmacokinetic variables as secondary outcomes.Results: Eight patients treated with lisdexamphetamine (n = 4), dexamphetamine (n = 1), methylphenidate (n = 1) and atomoxetine (n = 2) were included. In total, 409 samples were analysed. Patients underwent sleeve gastrectomy (n = 5) and Roux‐en‐Y gastric bypass (n = 3). AUC0–24 and Cmax of dexamphetamine increased after surgery in those using the prodrug lisdexamphetamine. There was no clear‐cut reduction in tmax postoperatively. For ritalinic acid and atomoxetine, no changes in AUC0–24 were observed, but for atomoxetine, a higher Cmax and a shorter tmax were observed postoperatively.Conclusion: Bariatric surgery may increase the systemic exposure of dexamphetamine after intake of lisdexamphetamine. Patients using lisdexamphetamine should be followed with regard to adverse drug reactions after bariatric surgery, and, if available, therapeutic drug monitoring should be considered.
- Open Access
- 20 October 2024
- Published by Elsevier in Epilepsy Research
- Vol. 208, 107469
Effects of sleeve gastrectomy and Roux-en-Y gastric bypass on pharmacokinetics of lamotrigine and valproate: A cohort study
- 20 October 2024
- Published by Elsevier in Epilepsy Research
- Vol. 208, 107469
Open AccessEffects of sleeve gastrectomy and Roux-en-Y gastric bypass on pharmacokinetics of lamotrigine and valproate: A cohort study
- Open Access
- 15 June 2023
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 45 (6) , 805-812
Effects of Sleeve Gastrectomy and Roux-en-Y Gastric Bypass on Escitalopram Pharmacokinetics: A Cohort Study
Background: Changes in the gastrointestinal physiology after bariatric surgery may affect the pharmacokinetics of medications. Data on the impact of different surgical techniques on the pharmacokinetics of commonly prescribed antidepressants such as escitalopram are limited. Methods: This case-only prospective study investigated escitalopram-treated patients who underwent bariatric surgery at hospitals in Central Norway. Escitalopram concentrations were assessed using serial blood samples obtained during a dose interval of 24 hours preoperatively and at 1, 6, and 12 months, postoperatively. The primary outcomes were changes in the area under the time–concentration curve (AUC0-24) with secondary outcomes, including full pharmacokinetic profiling. We performed repeated-measures analysis of variance for the AUC0-24 and secondary outcomes. Results: Escitalopram-treated obese patients who underwent sleeve gastrectomy (n = 5) and Roux-en-Y gastric bypass (n = 4) were included. Compared with preoperative baseline, dose-adjusted AUC0-24 values were within ±20% at all time points, postoperatively in the sleeve gastrectomy and oux-en-Y gastric bypass groups, with the largest changes occurring 1 month postoperatively (+14.5 and +17.2%, respectively). No statistically significant changes in any pharmacokinetic variables over time were reported; however, there was a trend toward increased maximum concentrations after surgery (P = 0.069). Conclusions: Our findings suggest that bariatric surgery has no systematic effect on the pharmacokinetics of escitalopram. However, because of the substantial interindividual variation, therapeutic drug monitoring can be considered to guide postoperative dose adjustments.
- 15 June 2023
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 45 (6) , 805-812
Open AccessEffects of Sleeve Gastrectomy and Roux-en-Y Gastric Bypass on Escitalopram Pharmacokinetics: A Cohort Study
Background: Changes in the gastrointestinal physiology after bariatric surgery may affect the pharmacokinetics of medications. Data on the impact of different surgical techniques on the pharmacokinetics of commonly prescribed antidepressants such as escitalopram are limited. Methods: This case-only prospective study investigated escitalopram-treated patients who underwent bariatric surgery at hospitals in Central Norway. Escitalopram concentrations were assessed using serial blood samples obtained during a dose interval of 24 hours preoperatively and at 1, 6, and 12 months, postoperatively. The primary outcomes were changes in the area under the time–concentration curve (AUC0-24) with secondary outcomes, including full pharmacokinetic profiling. We performed repeated-measures analysis of variance for the AUC0-24 and secondary outcomes. Results: Escitalopram-treated obese patients who underwent sleeve gastrectomy (n = 5) and Roux-en-Y gastric bypass (n = 4) were included. Compared with preoperative baseline, dose-adjusted AUC0-24 values were within ±20% at all time points, postoperatively in the sleeve gastrectomy and oux-en-Y gastric bypass groups, with the largest changes occurring 1 month postoperatively (+14.5 and +17.2%, respectively). No statistically significant changes in any pharmacokinetic variables over time were reported; however, there was a trend toward increased maximum concentrations after surgery (P = 0.069). Conclusions: Our findings suggest that bariatric surgery has no systematic effect on the pharmacokinetics of escitalopram. However, because of the substantial interindividual variation, therapeutic drug monitoring can be considered to guide postoperative dose adjustments.
- Open Access
- 1 November 2020
- Published by Elsevier in Clinical Therapeutics
- Vol. 42 (11) , 2232-2237
Effect of Sleeve Gastrectomy on Buprenorphine Pharmacokinetics: A Planned Case Observation
- 1 November 2020
- Published by Elsevier in Clinical Therapeutics
- Vol. 42 (11) , 2232-2237
Open AccessEffect of Sleeve Gastrectomy on Buprenorphine Pharmacokinetics: A Planned Case Observation
- 1 July 2018
- Published by Elsevier in Journal of Chromatography B
- Vol. 1089, 84-93
Quantification of 21 antihypertensive drugs in serum using UHPLC-MS/MS
- 1 July 2018
- Published by Elsevier in Journal of Chromatography B
- Vol. 1089, 84-93
Quantification of 21 antihypertensive drugs in serum using UHPLC-MS/MS
- 1 June 2018
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 38 (3) , 263-265
Systemic Inflammation Complicates the Interpretation of Therapeutic Drug Monitoring of Risperidone
- 1 June 2018
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 38 (3) , 263-265
Systemic Inflammation Complicates the Interpretation of Therapeutic Drug Monitoring of Risperidone
- 1 March 2018
- Published by Elsevier in Journal of Chromatography B
- Vol. 1077-1078, 7-12
Enantiomeric separation and quantification of R/S-amphetamine in urine by ultra-high performance supercritical fluid chromatography tandem mass spectrometry
- 1 March 2018
- Published by Elsevier in Journal of Chromatography B
- Vol. 1077-1078, 7-12
Enantiomeric separation and quantification of R/S-amphetamine in urine by ultra-high performance supercritical fluid chromatography tandem mass spectrometry